申请人:——
公开号:US20040176416A1
公开(公告)日:2004-09-09
Compounds having the formula (I),
Ar—(F)(E)-(CR
3
R
4
)—(CHR
5
)
m
-(T)-(Q)-Ar
1
,
are useful as CCR-3 receptor antagonists, wherein T is a bridged heterocyclyl group having one N atom and a bridge of one to two bridgehead carbon atoms; Ar and Ar
1
are aryl or heteroaryl; F is alkylene, alkenylene, or a bond; E is —C(═O)N(R
10
)—, —SO
2
N(R
10
)—, —N(R
11
)C(═O)N(R
10
O)—, —N(R
11
)SO
2
N(R
10
)—, —N(R
11
)C(═S)N(R
10
)—, —N(R
11
)C(═O)—, —N(R
11
)SO
2
—, —N(R
12
)C(═O)CH(R
13
)—, or CH(R
13
)C(═O)N(R
12
)—; Q is —C(═O)— or C
1-2
alkylene; and R
3
, R
4
, R
5
, R
9
, R
10
, R
11
, R
12
, and R
13
are defined as set forth in the specification.
具有以下化学式的化合物(I),Ar—(F)(E)-(CR3R4)—(CHR5)m-(T)-(Q)-Ar1,可用作CCR-3受体拮抗剂,其中T是具有一个N原子和一个到两个桥头碳原子的桥接杂环基团;Ar和Ar1是芳基或杂环芳基;F是烷基,烯烃基或键;E是—C(═O)N(R10)—,—SO2N(R10)—,—N(R11)C(═O)N(R10O)—,—N(R11)SO2N(R10)—,—N(R11)C(═S)N(R10)—,—N(R11)C(═O)—,—N(R11)SO2—,—N(R12)C(═O)CH(R13)—或CH(R13)C(═O)N(R12)—;Q是—C(═O)—或C1-2烷基;R3,R4,R5,R9,R10,R11,R12和R13如规范中所述定义。